Literature DB >> 7686364

Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.

Y Shakur1, J G Pryde, M D Houslay.   

Abstract

Full-length cDNA for the rat brain rolipram-sensitive cyclic AMP phosphodiesterase (PDE), RD1 was introduced into the expression vector pSVL. COS cells transfected with the recombinant vector pSVL-RD1 exhibited a 30-55% increase in homogenate PDE activity, which was abolished by rolipram (10 microM). Removal of the first 67 nucleotides of the RD1 cDNA yielded a truncated enzyme called Met26-RD1 which lacked the N-terminal first 25 amino acids. Whereas approx. 75% of RD1 activity was membrane-associated, Met26-RD1 activity was found exclusively in the cytosol fraction. Expression of RD1 nearly doubled membrane-associated PDE activity, while expression of Met26-RD1 increased cytosolic activity by approx. 30%. Membrane RD1 activity was found to be primarily associated with the plasma membrane, was not released by either high concentrations of NaCl or by a 'hypotonic shock' treatment, but was solubilized with low concentrations of Triton X-100. Phase separation of membrane components with Triton X-114 showed partition of RD1 into both the aqueous and detergent-rich phases, whereas Met26-RD1 partitioned exclusively into the aqueous phase. Both RD1 and Met26-RD1 specifically hydrolysed cyclic AMP; were unaffected by either Ca2+/calmodulin or by low cyclic GMP concentrations; exhibited linear Lineweaver-Burke plots with similar Km values for cyclic AMP (4 microM); both were potently and similarly inhibited by rolipram (Ki approx. 0.5 microM) and were similarly inhibited by cilostamide and 3-isobutyl-1-methylxanthine. Thermal inactivation, at 50 degrees C, showed that while the cytosolic-located fraction of RD1 (t0.5 approx. 3 min) and Met26-RD1 (t0.5 approx 3 min) were similarly thermolabile, membrane-bound RD1 was considerably more thermostable (t0.5 approx. 11 min). Treatment of both cytosolic RD1 and Met26-RD1 with Triton X-100 did not affect their thermostability, but solubilization of membrane RD1 activity with Triton X-100 markedly decreased its thermostability (t0.5 approx. 5 min). The N-terminal domain of RD1 appears not to influence either the substrate specificity or inhibitor sensitivity of this enzyme, but it does contain information which can allow RD1 to become plasma membrane-associated and thereby adopt a conformation which has enhanced thermostability.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686364      PMCID: PMC1134167          DOI: 10.1042/bj2920677

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  40 in total

1.  Brain low-Km cAMP phosphodiesterase.

Authors:  P de Mazancourt; Y Giudicelli
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

2.  Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated 'dense-vesicle' and peripheral-plasma-membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat.

Authors:  N J Pyne; N Anderson; B E Lavan; G Milligan; H G Nimmo; M D Houslay
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

3.  Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver.

Authors:  N J Pyne; M E Cooper; M D Houslay
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

4.  Molecular analysis of cDNA clones and the corresponding genomic coding sequences of the Drosophila dunce+ gene, the structural gene for cAMP phosphodiesterase.

Authors:  C N Chen; S Denome; R L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity.

Authors:  N J Pyne; M E Cooper; M D Houslay
Journal:  Biochem J       Date:  1987-02-15       Impact factor: 3.857

6.  Stereospecific binding of the antidepressant rolipram to brain protein structures.

Authors:  H H Schneider; R Schmiechen; M Brezinski; J Seidler
Journal:  Eur J Pharmacol       Date:  1986-08-07       Impact factor: 4.432

7.  Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase.

Authors:  J Colicelli; C Birchmeier; T Michaeli; K O'Neill; M Riggs; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

9.  Studies on the cellular location, physical properties and endogenously attached lipids of acylated proteins in human squamous-carcinoma cell lines.

Authors:  R A McIlhinney; J K Chadwick; S J Pelly
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

10.  Mitosis and inhibition of intracellular transport stimulate palmitoylation of a 62-kD protein.

Authors:  D I Mundy; G Warren
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

View more
  27 in total

1.  Cyclic AMP levels, adenylyl cyclase activity, and their stimulation by serotonin quantified in intact neurons.

Authors:  L C Sudlow; R Gillette
Journal:  J Gen Physiol       Date:  1997-09       Impact factor: 4.086

2.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).

Authors:  J C O'Connell; J F McCallum; I McPhee; J Wakefield; E S Houslay; W Wishart; G Bolger; M Frame; M D Houslay
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

4.  Co-transfection with protein kinase D confers phorbol-ester-mediated inhibition on glucagon-stimulated cAMP accumulation in COS cells transfected to overexpress glucagon receptors.

Authors:  E S Tobias; E Rozengurt; J M Connell; M D Houslay
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

Review 5.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

6.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

7.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.

Authors:  Y Shakur; M Wilson; L Pooley; M Lobban; S L Griffiths; A M Campbell; J Beattie; C Daly; M D Houslay
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

9.  Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions.

Authors:  M Lobban; Y Shakur; J Beattie; M D Houslay
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.